182 related articles for article (PubMed ID: 32009032)
1. [Unraveling the Pathogenesis of Inflammatory Bowel Disease and Search for New Therapeutic Medicines].
Hayashi S
Yakugaku Zasshi; 2020; 140(2):123-128. PubMed ID: 32009032
[TBL] [Abstract][Full Text] [Related]
2. Involvement of Embryo-Derived and Monocyte-Derived Intestinal Macrophages in the Pathogenesis of Inflammatory Bowel Disease and Their Prospects as Therapeutic Targets.
Zuo S; Jiang L; Chen L; Wang W; Gu J; Kuai J; Yang X; Ma Y; Han C; Wei W
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255764
[TBL] [Abstract][Full Text] [Related]
3. Research Progress of Interleukin-27 in Inflammatory Bowel Disease.
Wang Q; Chen F; Peng Y; Yi X; He Y; Shi Y
Inflamm Bowel Dis; 2024 Feb; 30(2):303-310. PubMed ID: 37540894
[TBL] [Abstract][Full Text] [Related]
4. Functional macrophages and gastrointestinal disorders.
Liu YH; Ding Y; Gao CC; Li LS; Wang YX; Xu JD
World J Gastroenterol; 2018 Mar; 24(11):1181-1195. PubMed ID: 29568199
[TBL] [Abstract][Full Text] [Related]
5. Macrophage polarization in inflammatory bowel disease.
Zhang K; Guo J; Yan W; Xu L
Cell Commun Signal; 2023 Dec; 21(1):367. PubMed ID: 38129886
[TBL] [Abstract][Full Text] [Related]
6. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.
Stojancevic M; Stankov K; Mikov M
Can J Gastroenterol; 2012 Sep; 26(9):631-7. PubMed ID: 22993736
[TBL] [Abstract][Full Text] [Related]
7. Advances in macrophage-targeting nanoparticles for the diagnosis and treatment of inflammatory bowel disease.
Liu S; Xia Y; Ji F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 52(6):785-794. PubMed ID: 37986666
[TBL] [Abstract][Full Text] [Related]
8. A new face of old cells: An overview about the role of senescence and telomeres in inflammatory bowel diseases.
Sienkiewicz M; Sroka K; Binienda A; Jurk D; Fichna J
Ageing Res Rev; 2023 Nov; 91():102083. PubMed ID: 37802318
[TBL] [Abstract][Full Text] [Related]
9. The progression of inorganic nanoparticles and natural products for inflammatory bowel disease.
Li Q; Lin L; Zhang C; Zhang H; Ma Y; Qian H; Chen XL; Wang X
J Nanobiotechnology; 2024 Jan; 22(1):17. PubMed ID: 38172992
[TBL] [Abstract][Full Text] [Related]
10. Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis.
Ouahed JD; Griffith A; Collen LV; Snapper SB
Inflamm Bowel Dis; 2024 Jul; 30(7):1189-1206. PubMed ID: 38280053
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Applications of Extracellular Vesicles in Inflammatory Bowel Disease.
Kim SH; Keum B; Kwak S; Byun J; Shin JM; Kim TH
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255819
[TBL] [Abstract][Full Text] [Related]
12. Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds?
Wang M; Shi J; Yu C; Zhang X; Xu G; Xu Z; Ma Y
Front Immunol; 2023; 14():1298186. PubMed ID: 38155971
[TBL] [Abstract][Full Text] [Related]
13. Plant-derived vesicle-like nanoparticles: A new tool for inflammatory bowel disease and colitis-associated cancer treatment.
Fang X; Feng J; Zhu X; Feng D; Zheng L
Mol Ther; 2024 Apr; 32(4):890-909. PubMed ID: 38369751
[TBL] [Abstract][Full Text] [Related]
14. Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy.
Zhao Y; He R; Zang J; Yin W; Su R; Xiong W; Xu W; Zhang J; Liu Y; Ren T; Huang Y; Li Y
J Nanobiotechnology; 2023 Nov; 21(1):444. PubMed ID: 37996883
[TBL] [Abstract][Full Text] [Related]
15. Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review.
Liu Y; Huang J; Li S; Li Z; Chen C; Qu G; Chen K; Teng Y; Ma R; Wu X; Ren J
Biomater Sci; 2024 Feb; 12(4):837-862. PubMed ID: 38196386
[TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities in inflammatory bowel disease: from current therapeutic strategies to organoid-based models.
Kong L; Chen S; Huang S; Zheng A; Gao S; Ye J; Hua C
Inflamm Res; 2024 Apr; 73(4):541-562. PubMed ID: 38345635
[TBL] [Abstract][Full Text] [Related]
17. Targeting B cells for inflammatory bowel disease treatment: back to the future.
Castro-Dopico T; Colombel JF; Mehandru S
Curr Opin Pharmacol; 2020 Dec; 55():90-98. PubMed ID: 33166872
[TBL] [Abstract][Full Text] [Related]
18. Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease.
Zaiatz Bittencourt V; Jones F; Doherty G; Ryan EJ
Inflamm Bowel Dis; 2021 Oct; 27(10):1684-1693. PubMed ID: 33693743
[TBL] [Abstract][Full Text] [Related]
19. Dual function of fungi-derived cytokines in inflammatory bowel diseases: protection or inflammation.
Sharifinejad N; Mahmoudi E
Gastroenterol Rep (Oxf); 2023; 11():goad068. PubMed ID: 38058517
[TBL] [Abstract][Full Text] [Related]
20. Targeting programmed cell death in inflammatory bowel disease through natural products: New insights from molecular mechanisms to targeted therapies.
Wang M; Wang Z; Li Z; Qu Y; Zhao J; Wang L; Zhou X; Xu Z; Zhang D; Jiang P; Fan B; Liu Y
Phytother Res; 2024 May; ():. PubMed ID: 38706097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
